5月20日，康方生物(09926)盘中下跌5.03%，截至10:47，报79.35元/股，成交12.31亿元。
康方生物科技(开曼)有限公司是一家集研发、生产和商业化创新抗体新药的全球领先生物制药公司，专注于肿瘤、自身免疫、炎症等重大疾病的源头创新。公司拥有50个以上自主知识产权的创新候选药物，其中24个处于临床开发阶段，并已成为中国在研管线最丰富的创新抗体药物研发企业之一。
截至2024年年报，康方生物营业总收入21.24亿元、净利润-5.15亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.